trending Market Intelligence /marketintelligence/en/news-insights/trending/DozGoAb4mGmLG6JF1qCY8Q2 content esgSubNav
In This List

Japan approves Takeda's multiple myeloma treatment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Japan approves Takeda's multiple myeloma treatment

The Japanese Ministry of Health, Labour and Welfare approved Takeda Pharmaceutical Co. Ltd.'s Ninlaro capsules for the treatment of multiple myeloma, a cancer of plasma cells.

Ninlaro is indicated in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have not responded to standard therapy or who have relapsed after treatment.

The approval is based on a phase 3 trial which demonstrated that the combination treatment increased median progression-free survival by about 6 months or 40% compared to placebo, lenalidomide, and dexamethasone.